Cathay Biotech (688065.SH) released a performance forecast for the first quarter of 2024. It is expected to achieve revenue of 650 million yuan to 720 million yuan in the first quarter of 2024, an increase of 28.60% to 42.45% over the previous year. Net profit attributable to shareholders of listed companies is expected to be between 94 million yuan and 115 million yuan in the first quarter of 2024, an increase of 63.65% to 100.20% over the previous year. It is estimated that in the first quarter of 2024, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss will be 91 million yuan to 112 million yuan, an increase of 79.04% to 120.36% over the previous year.
凯赛生物(688065.SH)发预增，一季度净利9400万元至1.15亿元，同比增长63.65%至100.20%
Kaisai Biotech (688065.SH) increased in advance, with net profit of 94 million yuan to 115 million yuan in the first quarter, an increase of 63.65% to 100.20% over the previous year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.